ARTICLE | Clinical News
Tetraphase preclinical data
June 17, 2013 7:00 AM UTC
In vitro, TP-271 demonstrated activity against major CABP pathogens, including Legionella pneumophila, Chlamydia pneumonia and Mycoplasma pneumonia. The minimum inhibitory concentration of TP-271 with...